

Legacy Policy for all Full Insured and some ASO Group effective 12.14.2024.

Genetic Testing - Cardioneurovascular and Developmental Diagnosis, Medical 34C

Table of Content	Effective Date	2/2009
Purpose		
Description & Definitions	Next Review Date	N/A
<u>Criteria</u>		,
Coding	Coverage Policy	Modical 04C
Document History	<u>Coverage Folicy</u>	Meulcal 34C
References		
<u>Special Notes</u>	<u>Version</u>	2
Keywords		

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details <u>*</u>.

Purpose:

This policy addresses genetic testing for cardio-, neuro-, vascular and developmental diagnosis.

Description & Definitions:

Autosomal recessive: A genetic condition that appears only in individuals who have received two copies of an autosomal gene, one copy from each parent. The gene is on an autosome, a nonsex chromosome. The parents are carriers who have only one copy of the gene and do not exhibit the trait because the gene is recessive to its normal counterpart gene

X-linked recessive inheritance - hereditary pattern in which a recessive gene on the X chromosome results in the manifestation of characteristics in male offspring and a carrier state in female offspring

Criteria:

Genetic Testing is considered medically necessary for the prevention, diagnosis and treatment of patients who meet **ALL** of the following:

- There must be **1 or more** of the following:
 - There is sufficient Published Scientific Evidence or 3rd party Consensus in the Medical Community that the results of the specific genetic Testing improves clinical outcomes
 - There is an approved mutation specific treatment available
- The genetic disorder is associated with a potentially significant disability or has a lethal natural history
- The results of the genetic test could impact the medical management of the individual

• After completion of a thorough history, physical examination, pedigree analysis, genetic counseling, relevant diagnostic and biochemical tests (if any), the patient meets criteria for **1 or more** of the following approved tests:

- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) DNA testing for 1 or more of the following indications if ordered by a geneticist:
 - Symptomatic individual younger than 60 years of age with a family history consistent with an autosomal dominant pattern of inheritance of this condition
 - Pre-symptomatic individuals younger than 60 years of age with a family history consistent with an autosomal dominant pattern of inheritance and a known mutation in an affected member of the family
- **Cystic Fibrosis** for Carrier Testing for **1 or more** of the following:
 - Common mutations included in CPT codes 81221 (familial variants) or 81220 (common variants) are covered without precertification.
 - Extended CFTR mutation panels (Code 81222 and 81224) are approved for patients meeting 1 or more of the following:
 - Individuals with reproductive partners with cystic fibrosis or congenital absence of the vas deferens and no identified mutation with standard gene sequencing
 - Individuals with a family history of cystic fibrosis with no identified mutation on basic/standard gene sequencing
 - Individuals with elevated or indeterminate sweat chloride levels where from zero to up to 2 mutations have been identified by basic/standard gene sequencing
- Fragile X syndrome testing for FMR1 (81243 and/or 81244) is covered on request.
- Long QT Genetic Testing (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2 genes) for 1 or more of the following:
 - For individual with a prolonged QT interval on resting electrocardiogram (a corrected QT interval (QTc) of 450 msec without an identifiable external cause for QTc prolongation (such as heart failure, bradycardia, electrolyte imbalances, certain medications and other medical conditions)
 - Individual with first-degree relatives (siblings, parents, offspring) with a known or suspected LQT mutation, or long QT syndrome.
- **Muscular Dystrophy** genetic testing may be indicated when the appropriate clinical situation is present, as indicated by **1** or more of the following:
 - The individual has unexplained progressive muscle weakness, abnormal gait, or other clinical findings consistent with muscular dystrophy or spinal muscular atrophy. These findings may also include abnormal laboratory findings (e.g., elevated creatine kinase serum (CK)), or a positive family history
 - The individual has a confirmed diagnosis of muscular dystrophy and genetic testing is required to establish the disease-causing mutation
 - Test is **1 or more** of the following:
 - Congenital Muscular Dystrophy panel including **ANY** of the following: (ACTA1, AMPD1, AMPD3, CAPN3, CAV3, COL6A1, COL6A2, COL6A3, DES, DMD, DYSF, EMD, FKRP, FKTN, ITGA7, LAMA2, LARGE, LMNA, MYOT, NEB, PEX1, PEX12, PEX14, PEX2, PEX26, PEX3, PEX5, PEX6, PLEC, PMM2, POMGNT1, POMT1, POMT2, RYR1, RYR2, SEPN1, SGCA, SGCB, SGCD, SGCE, SGCG, SIL1, TCAP, TNNI2, TNNT1, TPM2, TPM3, TRIM32, TTN, ANO5)
 - Duchene Muscular Dystrophy (DMD)
 - Emery-Dreifuss Muscular Dystrophy (EDMD1, 2, and 3)(FGFR2)
 - Familial Myotonic Dystrophy, (DMPK, DM2, ZNF9, or CNBP)
 - Fascioscapulohumeral Muscular Dystrophy (FSHD, FSHMD1A, FGFR3)
 - Limb girdle Muscular Dystrophy (LGMD1, LGMD2) (FKRP (Fukutin related protein))
 - Ullrich Muscular Dystrophy (COL6A2)

Karyotype (cytogenetic analysis) (88289/88230) is covered without preauthorization.

Fanconi Anemia (81242/88248) genetic Testing for 1 or more of the following:

- Patient of Ashkenazi Jewish ancestry and of reproductive age
- Patient with family history of Fanconi anemia, and prior identification of disease-causing mutations in relatives
- Prior to gamete donation if gamete recipient is carrier
- Reproductive partner of FANC gene mutation carrier
- Equivocal or indeterminate cytogenetic testing for chromosomal breakage or rearrangement in presence of DNA interstrand cross-linking agent (eg, diepoxybutane or mitomycin C)
 - Identification of disease-causing mutation in patient with confirmed diagnosis
- o Retinoblastoma (RB1 gene) testing may be indicated when ALL of the following are present:

- Diagnosis or screening for hereditary retinoblastoma, as indicated by 1 or more of the following:
 - First-degree relative of patient with known RB1 mutation
 - Patient with retinoblastoma, with or without family history of retinoblastoma
 - Preimplantation genetic diagnosis for families in which disease-causing mutation has been identified
 - Prenatal diagnosis for¹ pregnancies at increased risk when disease-causing allele of affected family member has been identified or linkage has been established in family sting is accompanied by genetic counseling.
- Testing is accompanied by genetic counseling
- **Familial Hemophagocytic Lymphohistiocytosis** is covered if requested by name without criteria (there is **no specific code**).
- Other Disorders testing for All of the following:
 - Disorder is **1 or more** of the following:
 - Bloom syndrome, (BLM Gene)
 - Canavan disease, (ASPA Gene)
 - Deficiency, Familial hyperinsulinism,
 - Dihydrolipoamide dehydrogenase
 - Dysautonomia (Riley-Day syndrome),
 - Fanconi anemia (FANC Genes)
 - Gaucher's disease,
 - Glycogen storage disease type 1 (G6PC and SLC37A4 Genes
 - Huntington Disease (HTT gene)
 - Inheritest Universal screening
 - Maple syrup urine disease BCKDHA, BCKDHB, and DBT Genes)
 - Mucolipidosis IV, (MCOLN1 Gene)
 - Nemaline myopathy,
 - Nieman Pick Disease Type A, (SMPD1, NPC1, and NPC2 Genes)
 - Usher syndrome type 1F or Usher syndrome type 3
 - Criteria must be met for appropriateness with 1 or more of the following:
 - Individual with positive family history or known mutation of the disease in the family
 - Reproductive partner of known gene mutation carrier
 - Equivocal or indeterminate diagnostic testing of a symptomatic individual
 - Need to establish disease-causing mutation in individual with confirmed diagnosis
- Marfan syndrome (FBN1 gene testing) for Marfan syndrome for 1 or more of the following:
 - Individual does not fulfill Ghent diagnostic criteria but has one major feature of Marfan syndrome
 - Individual is a first-degree relative of an individual with known disease-causing variants
 - CGH Array or SNP Microarray (single nucleotide polymorphism) is considered medically necessary for patients under the age of 13 (under age 21 for EPSDT) and 1 or more of the following criteria below is met:
 - Individual has multiple anomalies not specific to a known genetic syndrome
 - Individual has apparently non-syndromic developmental delay or intellectual disability
 - Individual with Autism spectrum disorders.
 - Neurofibromatosis 1 and 2 for 1 or more of the following:
 - NF1 (81408) gene testing for **1 or more** of the following:
 - Diagnosis of neurofibromatosis type 1 uncertain after clinical evaluation and conventional diagnostic testing
 - NF2 (81405) gene testing for **1 or more** of the following:
 - Diagnosis of neurofibromatosis type 2 uncertain after clinical evaluation and conventional diagnostic testing
 - Patient with bilateral vestibular schwannomas
 - Patient with multiple spinal tumors (schwannomas, meningiomas, gliomas)
- Familial Hypercholesterolemia is considered medically necessary for requests meeting All of the following:
 - Must be **1 or more** of the following:
 - Plasma cholesterol level in an adult over the age of 18 greater than or equal to 310 mg/dL

0

- Plasma cholesterol level in a child (<18 y/o) greater than or equal to 230 mg/dL
- Have any **1 or more** of the following:
 - Family history of premature coronary heart disease (men < 55 years of age, women < 60 years of age) or sudden cardiac death (an unexpected death due to cardiac causes that occurs in a short time period [generally within 1 hour of symptom onset]);
 - Presence of **xanthomas** on physical Exam
 - Known family history (first or second degree relative) with familial hypercholesterolemia and/or any of the associated mutations.
- Familial Mediterranean Fever (FMF) (MEFV gene) testing may be indicated when clinical findings or diagnostic testing are suggestive of familial Mediterranean fever, as indicated by 1 or more of the following:
 - Amyloidosis (senile systemic type)
 - Favorable response to colchicine therapy
 - Recurrent episodes of fever associated with 2 or more of the following:
 - Acute abdominal pain with possible peritoneal signs
 - Acute arthritis of ankle, knee, or hip
 - Elevated erythrocyte sedimentation rate or C-reactive protein
 - Elevated serum fibrinogen
 - Erysipelas-like erythema of skin[C]
 - Leukocytosis
 - Pleuritis
 - First-degree relative of individual with confirmed diagnosis of familial Mediterranean fever
- Ashkenazi Jewish genetic panel testing may be indicated when ALL of the following are present:
 - Individual to be tested is of Ashkenazi Jewish ancestry and of reproductive age
 Panel testing is being ordered to assess for mutations associated with 3 or more of the
 - following diseases:
 - Bloom syndrome
 - Canavan disease
 - Cystic fibrosis
 - Dihydrolipoamide dehydrogenase deficiency
 - Familial dysautonomia (Riley-Day syndrome)
 - Familial hyperinsulinism
 - Fanconi anemia group C
 - Gaucher disease
 - Glycogen storage disease type 1A
 - Joubert syndrome 2
 - Maple syrup urine disease
 - Mucolipidosis IV
 - Nemaline myopathy
 - Niemann-Pick disease type A
 - Spinal muscle atrophy
 - Tay-Sachs disease
 - Usher syndrome type 1F
 - Usher syndrome type 3

Spinal Muscular Atrophy genetic testing of the SMN1 and SMN2 genes may be indicated when the appropriate clinical situation is present, as indicated by **1 or more** of the following:

- Symmetric flaccid paralysis in infants
- Poor muscle tone in infants
- Lack of motor development in infants (i.e., the ability to sit without support was never achieved)
- Diffuse symmetric proximal muscle weakness that is greater in the lower than upper limbs (this may be evident by frequent falls, abnormal gait, etc.)
- Markedly decreased deep tendon reflexes
- Progressive muscle weakness
- Prospective parents who wish to reproduce
- Hereditary Hypertrophic Cardiomyopathy (HCM) individual mutation diagnostic or screening testing is covered for panels up to 20 mutations: (ACTC (ACTC1), CAV3, GLA, LAMP2, MTTG, MTTI,

MTTK, MTTQ, MYBPC3, MYH7, MYL2, MYL3, PRKAG2, TNNC1, TNNI3, TNNT2, TPM1, TTR) may be indicated when **ALL** of the following are present:

- Confirmation of diagnosis in individual with clinical manifestations suggestive of hypertrophic cardiomyopathy
- The member is the first-degree relative of an individual with hypertrophic cardiomyopathy
- Testing is accompanied by genetic counseling
- **Mucopolysaccharidosis IVA (Morquio syndrome)** may be confirmed by **1 or more** the following criteria:
 - Documented clinical signs and symptoms of the disease (e.g., kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency, etc.)
 - Documented reduced fibroblast or leukocyte GALNS enzyme activity
 - Molecular genetic testing of GALNS
- **CD40 Ligand Deficiency (also known as CD40LG or X-Linked Hyper IgM)** testing may be confirmed by genetic testing when **1 or more** the following criteria are met:
 - The individual has at least one first- or second- degree relative with X-Linked Hyper IgM syndrome
 - The individual has an absent or decreased expression of the CD40 ligand (CD40L) protein on flow cytometry
 - The individual has clinical characteristics indicative of X-linked hyper IgM syndrome (examples include, but are not limited to low serum concentrations of IgG and IgA and normal or elevated serum concentrations of IgM, neutropenia, thrombocytopenia, anemia, autoimmune and/or inflammatory disorders, or recurrent upper and lower respiratory tract bacterial infections, opportunistic infections, and recurrent or protracted diarrhea associated with failure to thrive)
- Hereditary Fructose Intolerance Testing (ALDOB Gene) testing for specific mutation if known in a family or panel specific mutation is unknown, based on family history and clinical features requiring a specific diagnosis.
- Tay-Sach's disease (HEXA gene) is approved for 1 or more of the following:
 - Carrier testing for 1 or more of the following:
 - Individual of Ashkenazi Jewish ancestry and of reproductive age
 - Individual with deficiency of beta-hexosaminidase A enzyme activity on carrier screening assay
 - Individual with family history of Tay-Sachs disease and of reproductive age, when both disease-causing mutations in HEXA gene have been identified in affected relative
 - Prior to gamete donation if gamete recipient is carrier
 - Confirmation of diagnosis of Tay-Sachs disease in symptomatic patient with inconclusive leukocyte or serum activity of beta-hexosaminidase A
 - Establishment of disease-causing mutation in patient with confirmed diagnosis of Tay-Sachs disease
 - Preimplantation genetic diagnosis when disease-causing mutation in HEXA gene has been identified in both parents
 - Prenatal diagnosis when disease-causing mutation in HEXA gene has been identified in both parents
 - Wiskott-Aldrich syndrome (WAS) gene mutation testing 1 or more of the following:
 - Individual is male with All of the following:
 - Initial testing points to a WAS related disorder (Wiskott Aldrich Syndrome, X linked thrombytopenia, X-linked congenital neutropenia)
 - Individual is female with **All** of the following:
 - There is a known family history of WAS gene mutation (testing is to identify female carriers)
 - Testing is prenatal with All of the following indications:
 - Fetus is male. Testing is being done with chorionic villi sampling or cultured amniocytes.
 - There is known risk of WAS gene mutation (positive family history of WAS gene mutation and/or of known positive carrier females)
- **Phenylalanine hydroxylase (PAH) Testing** is medically necessary to confirm phenylketonuria (PKU) diagnosis.

- McKusick-Kaufman Syndrome Single Gene Test testing is considered medically necessary for All of the following:
 - Individual displays symptoms
 - Definitive diagnosis is uncertain
 - Test will influence treatments for disabilities and need for future care
 - Follow up laboratory testing will be required dependent on diagnosis
- **CYP21A genetic testing for congenital adrenal hyperplasia** testing is considered medically necessary for **1 or more** of the following:
 - Completed baseline serum 17-hydroxyprogesterone (17OHP) level as borderline or elevated
 - Cosyntropin stimulation test completed (ACTH stimulation test)
- SERPINA1 gene testing may be indicated when ALL of the following are present:
 - Diagnosis or screening for alpha-1 antitrypsin deficiency, as indicated by 1 or more of the following:
 - Confirmation of diagnosis in individual with clinical manifestations suggestive of
 - alpha-1 antitrypsin deficiency, as indicated by 1 or more of the following:
 - o Bronchiectasis
 - Chronic obstructive pulmonary disease and low serum alpha-1 antitrypsin level
 - Infant with cholestatic liver disease
 - o Panniculitis
 - Unexplained liver disease (eg, chronic hepatitis with or without cirrhosis, chronically elevated aminotransferase levels, portal hypertension, or primary liver cancer) and low serum alpha-1 antitrypsin level
 - Predictive testing for at-risk first-degree adult relative,[E] when both disease-causing mutations in SERPINA1 gene have been identified in affected relative
 - Predictive testing for at-risk asymptomatic first-degree pediatric relative,[E] when both disease-causing mutations in SERPINA1 gene have been identified in affected relative with childhood liver disease[F]
 - Preimplantation genetic diagnosis,[G] when disease-causing SERPINA1 gene mutations have been identified in relative with childhood liver disease
 - Prenatal testing,[H] when disease-causing SERPINA1 gene mutations have been identified in relative with childhood liver disease
- Friedreich Ataxia (FXN) Diagnosis or carrier Gene testing may be indicated 1 or more of the following:
 - Carrier testing in at-risk relative when disease-causing FXN gene mutation has been identified in family
 - Carrier testing in reproductive partner of known FXN mutation carrier
 - Confirmation of diagnosis in patient with clinical findings suggestive of Friedreich ataxia
 - Preimplantation genetic diagnosis, when disease-causing mutation in FXN gene has been identified in both parents
 - Prenatal diagnosis, when disease-causing mutation in FXN gene has been identified in both parents

The following tests and/or conditions are considered **not medically necessary** for any use other than those indicated in clinical criteria, to include but not limited to:

- Achilles Tendinopathy
- Adams-Oliver syndrome
- Adenylosuccinate Lyase Deficiency
- Aerobic Capacity
- Alagille Syndrome
- Alcohol flush
- Alpers-Huttenlocher syndrome
- Alpha and Beta Thalassemia (HBB)
- Alport gene testing
- Ambry EpiFirst Focal

- Ambry's Cystic Fibrosis 508 First and reflex testing if negative to Cystic Fibrosis Gene Sequencing Analysis
- Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease)
- Angelman syndrome (AS)
- Angelman-Like Syndromes
- Antley-Bixler syndrome
- Apelin
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)

- Autosomal Dominant Nocturnal Frontal Lobe Epilepsy
- Autosomal Dominant Partial Epilepsy with Auditory Features
- Baltic Myoclonus (Unverricht-Lundbord Disease)
- Beckwith Wiedemann Syndrome
- Benign Familial Neonatal Seizures
- Benign Familial Neonatal-Infantile Seizures (Bfnis)
- Bernard-Soulier Syndrome Gene
- Betaglobulin
- Biotinidase deficiency
- Birt-Hogg-Dubé syndrome
- Bitter Taste
- Blood Pressure Response to Exercise
- BMI Response to Exercise
- Brugada syndrome
- C3 Glomerulonephritis Sequencing Panel
- CardiaRisk AGT
- Carnitine SLC
- Catecholaminergic Polymorphic Ventricular Tachycardia
- Choroidal neovascularization
- Chronic progressive external ophthalmoparesis (CPEO)
- Citrullinemia
- Clarava[™]
- Coffin Lowry syndrome (RPS6KA3)
- Coffin Siris syndrome
- Combimatrx's CombiSNP reflex
 escalation testing
- Congenital Neutropenia Panel
- Connective Tissue Disorders: Sequencing Panels
- Coronary artery disease
- Courtagen genetic panels
- Craniosynostosis
- Creatine Deficiency Syndromes
- Cryopyrin-associated Period Syndrome
 (CAPS)
- Cytochrome P450 OxidoReductase (POR) Deficiency with Disordered Steriodogenesis
- Cytogenomic constitutional (genome-hyphenwide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities [not covered for cardiovascular disease risk]
- deCODE AF
- deCODE MI
- devACT neurodevelopmental panel
- devSEEK neurodevelopmental
 panel

- Diabetes type 2 genetic testing
- DiGeorge Syndrome (AKA Velocardiofacia syndrome, Familial third and fourth pharyngeal pouch syndrome, Sedlackova syndrome, and Thymic aplasia syndrome)
- Dilated cardiomyopathy panels
- Dravet Syndrome
- Duane-Radial Ray syndrome / Acro-Renal-Ocular syndrome
- Eating disinhibition
- Ehlers-Danlos Syndrome can be diagnosed with a skin biopsy.
- Ellis-van Creveld syndrome
- Emory University's Epilepsy and Seizure Disorders: Sequencing Panel
- Epidermodysplasia Verruciformis
- Epidermolytic hyperkatosis
- Epilepsy Advanced Sequencing Evaluation
- EpiNext
- epiSEEK Comprehensive epilepsy panel
 - epiSEEK focus epilepsy panel
- Exome Sequence Analysis (CPT 81415, 81416, 81417)
- Familial cold urticaria/familial cold autoinflammatory syndrome
 Familial Congenital Cavernous
- Malformations (FCCM),
 Fascioscapulohumeral M
- Fascioscapulohumeral Muscular Dystrophy (FSHD)
- Fatty Acid Oxidation Panel for Glutaric Aciduria Type 2
- Fever Mutation Panel
- Gene Dx Comprehensive Cardiomyopathy
 Panel
- GeneDx Arrhythmia panel
- GeneDX Arthrogryposis Panel Test
- GeneDx Combined Cardiac panel
- Genetic risk due to decreased vitamin B2
- Genetic risk for decreased adiponectin
- Genetic risk for decreased folate
- Genetic risk for decreased HCL cholesterol
- Genetic risk for decreased omega-6 and omega-3
- Genetic risk for decreased vitamin A
- Genetic risk for decreased vitamin B12
- Genetic risk for decreased vitamin B6
- Genetic risk for decreased vitamin C
- Genetic risk for decreased vitamin D
- Genetic risk for elevated LDL cholesterol
- Genetic risk for elevated trigylcerides
- Genetic risk for increased vitamin E
- Genome Sequence Analysis (CPT 81425, 81426, 81427)
- Hemiplegic Migraine Panel

- Hepatocerebral mtDNA Depletion
 Panel
- Hereditary Hemorrhagic Telangectasias;
- Hereditary Hemorrhagic Telangiectasias
- Hereditary Multiple Exostoses
- Hereditary Multiple Osteochondromatosis
- Hereditary pancreatitis
- Hereditary Retinal Disorders Genetic Panel Lab Test
- Hereditary sensory and autonomic neuropathies genetic testing
- Hereditary Spastic Paraplegia
- · Hereditary spherocytosis and elliptocytosis
- Hunter syndrome
- hyper IgE syndrome
- Hyperhomocysteinemia
- Hyperimmuneoglobulin D Syndrome
- Hypohidrotic Ectodermal Dysplasia Gene
- Hypokalemic Periodic Paralysis
- Idiopathic Progressive Polyneuropathy Gene
- Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified [adiponectin] [leptin] [interleukin-hyphen6 (IL-6)] [tumor necrosis factor alpha (TNF-a)] [Oxidized phospholipids] [interleukin 17] [tolllike receptor 4 (TLR4)] [Interleukin-18 (IL-18)] [soluble cell adhesion molecules (e.g., intercellular adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [ICAM-1], [E-hyphenselectin, P-hyphenselectin)] [transforming growth factor beta]
- Impulse Control, ADHD, Oppositional , Defiance Disorder
- Incontinentia Pigmenti
- Inherigen Plus
- Inheritest
- Invitae Alternating Hemiplegia of Childhood Panel
- Isovaleric Acidemia
- Jaundice Chip array
- Juvenile Myoclonic Epilepsy
- Klippel-Feil syndrome
- Klippel-Feil syndrome
- Lafora Disease
- Leber's hereditary optic neuropathy panel
- Legius Syndrome
- Leopard syndrome
- Lesch-Nyhan Syndrome
- Liddle syndrome
- Lissencephaly
- Loeys-Dietz syndrome
- Low Bone Mass Panel for Osteoporosis
- IysoSEEK lysosomal disorder panel
- McCune-Albright syndrome

- Medium Chain Acyl-coA Dehydrogenase Deficiency (MCADD)
- Metachromatic leukodystrophy (MLD)
- Microarray and multi-gene panels for nonsyndromic hereditary hearing loss
- Microcephaly with Early-Onset Intractable Seizures and Developmental Delay (MCSZ)
- Microdeletion Syndromes on Chromosome 1-11 including but not limited to the following:
 - TAR syndrome
 - Smith-Magenis syndrome
 2g37 Syndrome
 - Wolf-Hirschhorn Syndrome
 - Sotos Syndrome
 - Williams Syndrome
 - Nablus Mask-Like Facial Syndrome
 - Langer-Giedion Syndrome Or Trichorhinophalangeal Syndrome Type II
 - Digeorge Syndrome Typell
 - o Wagr Syndrome
 - Potocki-Shaffer Syndrome
 Jacobsen Syndrome
 - Migrainous vertigo
 - Mitochondrial Disorder testing
- Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)
- Mosaic Down Syndrome
- Mowat-Wilson Syndrome
- mtSEEK comprehenseive nuclear mitochondrial panel
- Muckle Wells syndrome
- Muckle Wells syndrome
- Mucopolysaccharidosis
- Myopathy/Rhabdomyolysis panel
- Nail-Patella Syndrome
- Natera Renasight Genetic Panel
- Neimann Pick Disease;
- Neonatal Onset Multisystemic Inflammatory
 Disorder
- Nephrotic Syndrome
- Neuronal Ceroid Lipofuscinoses
- Noonan syndrome
- Nuclear encoded mitochondrial genomic sequencing panels (eg, Nuclear-Mito NGS Panel)
- nucSEEK focus nuclear mitochondrial gene panel
- Oculocutaneous albinism
- Oculopharyngeal muscular dystrophy
- Ohtahara Syndrome
- Osteogenesis imperfecta
- Osteoprotegerin
- Parkinson's Disease

- Pendred syndrome
- Periodic fever syndrome panel
- Pfeiffer syndrome
- Polycystic kidney disease
- Pontocerebellar hypoplasia genetic testing
- Prader-Willi Syndrome gene testing •
- PreDx Diabetes Risk Test;
- Primary dystonia;
- Progressive Myoclonic Epilepsy (PME)
- Pulmonary Alveolar Proteinosis next generation sequencing or mutation testing
- **Pyridoxine Dependent Seizures** •
- Repeat/Duplicative genetic testing
- Retinitis Pigmentosa genetic testing •
- **Rett/Atypical Rett Syndrome** •
- Schizencephalv
- Scoliscore test
- Selective Serotonin Reuptake Inhibitors (SSRIs) - Cytochrome P450 Polymorphism Testina
- Septo-Optic Dysplasia (SOD) ٠
- Short Stature Homeobox testing

- Shwachman-Diamond syndrome
- **Skeletal Disorders Panel**
- Sleep-walking
- Soto syndrome
- Stickler Syndrome
- Trismus Pseudocamptodactyly Syndrome
- Trismus-pseudocamptodactyly syndrome
- Tuberous Sclerosis testing
- Tumor Necrosis Factor Receptor-associated Periodic Syndrome
- Tuteva™
- Uniparental Disomy
- VICI Syndrome
- Waardenburg Syndrome
- West Syndrome
- Whole Exome Sequencing (WES)
- Whole Genome Sequencing (WGS)
- Wilson disease
- X chromosome activation status testing
- xTAG Gastrointestinal Pathogen Panel

CHST14

CHST8

CIDEC

CLN3

CLN5

CLN6

CLN8

COCH

CNTNAP2

COL11A1

COL11A2

COL1A1

COL1A2

COL2A1

COL3A1

COL5A1

COL5A2

COL7A

COL7A1

CPT11

CRYAB

CRYM

CSF2RA

CSF2RB

CSRP3

CSTB

CTLA4

Page 10 of 19

CLDN14.

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

The following genes are considered not medically necessary for any use other than those indicated in clinical criteria, to include but not limited to:

- ABCA1 •
- ABCA3
- ABCC8 •
- ABCC9 •
- ACTA2
- ACTG1 •
- ACTN2
- ACVR1 •
- ACVRL1 (ALK1) •
- ADAMTS2 •
- ADIPOQ •
- AGPAT2 AGT
- AKT2 •
- ALDH2
- ALDH7A1 •
- •
- ANGPTL4 •
- ANKK1
- ANKRD1 •
- APOA2 APOE •
- •
- ARHGAP31 ARHGEF9
- ARID1A •
- ARID1B
- ARX •
- ASS1
- ATN1
- ATP6AP2
- ATP6V0A2
- ATP7B
- Medical 34C

- BAG3 BESC1 BESC3
- BS
- BSCL2
- C3
- CAD
- CASK
- CASQ2
- CAV1
- CAV3 •
- CCDC50.
- CD151 •
- CD25 (IL2RA)
- CDH23.
- CDKAL1
- CDKL5
- CDKN1C
- CDKN2B .
- CDSN
- CETP
- CFB •
- CFH •
- CFHR5 •
- CFI •
- **CFTR Full Gene Sequencing** • (81223)
- CHD7
- CHRNA2 •
- CHRNA4
- CHRNB2 •

- Chromosome 4 Deletion Gene
- Chromosome 9 polymorphism • 9p21

- CTSD •
- DAX-1 •
- DES •
- DFNA5 •
- DIAPH1 • DOCK6
- • DOCK8
- DRD2 •
- DSG2 •
- DSP •
- DSPP
- DST •
- DTNA •
- EDN1
- EGR2 •
- ELANE •
- ELN •
- EMD •
- ENG •
- EOGT •
- EPM2A
- EPM2B • **ESPN**
- ESR1 •
- **ESRRB** •
- EVC •
- EVC2 •
- EXOSC8 •
- EXPH5 •
- EXT1 •
- EXT2 •
- Factor H •
- FBLN5 •
 - FBN2 •
 - FCAS
 - FERMT1 •
 - FGFR1 •
 - FKBP14 •
 - FKTN
 - FLCN •
 - FMR2
 - FOXF1 •
 - FSGS ٠
 - FTO •
 - GABRG2 •
 - GAMT ٠
 - GATAD1
 - GATM •
 - GCK •
 - GDAP1 •
 - GDF5 •
 - GFI1 • •
 - GIPC3 GJB1, •
 - GJB2
 - GJB3 •

GJB6 gene (Connexin • 30)

LITAF

LMNA

LMX1B

LOXHD1,

LRTOMT

MAP2K1

MAP2K2

MC4R

MECP2

MFSD8

miR-182

miR-183

miR-96

MMAB

MMP3

MTHFR

MTND1

MTND5

MTND6

MTNR1B

MT-RNR1

MTTD

MTTG

MTTH

MTTI

MTTK

MTTL1

MTTL2

MTTM

MTTQ

MTTS1

MT-TS1

MTTS2

MYBPC3

MYH14,

MYH7

MYH8

MYH9

MYL3

MYLK

MYLK2

MYO15A

MYO1A

MYO3A

MYO6.

MYO7A

MYOZ2

MYPN

NEBL

NEFL

NEXN

Page 11 of 19

MPZ

MID1

MCP

MARVELD2

Menopause Karotype

٠

•

•

•

•

٠

•

٠

•

٠

•

•

•

•

•

•

•

•

•

٠

•

•

•

•

•

٠

•

•

•

٠

•

•

٠

٠

٠

•

٠

٠

•

•

•

•

٠

•

•

•

•

•

•

•

•

•

•

- GLA •
- GLIS2/NPHP7
- GLUD1 •
- •
- GPR56 gene •
- GPSM2,
- GRHL2. •
- GRIN2A •
- (ST2) •
- HADH
- HAX1 •
- HBA1 •
- HBA2
- HBB •
- HESX1
- HHEX •
- HNF1A
- HNF1B •
- HNF4A •
- HPRT1
- HRAS •
- IGF2BP2 •
- ILK
- **INSIG2** •
- **ITGA3** •
- ITGA6
- ITGB4 •
- JAG1
- JAZF1
- JPH2
- JUP
- KCNC2
- KCNC3
- KCNJ11 •
- KCNQ1 • •
 - KCNQ1OT1 (also known as LIT1)
- KCNQ2
- KCNQ3 •
- KCNQ4 •
- KCNT1 •
- KCTD10 •
- KLP6 •
- KRT14 •
- KRT5 •

•

•

•

•

•

•

•

•

•

L1CAM •

LAMA4

LAMB2

LAMC2

LAMP3

LEMD3

Leptin

LGI1

LIPC

LDB3 (ZASP)

 PLP 	 SLC25A13 	 TPRQ
 PMP22, 	• SLC25A20	• TREX1
PNPO	• SLC25A22	TRIOBP
POLG	• SLC2A10	 TSC1
 POU4F3 	SLC2A2	 TSC2
PPARD	• SLC30A8	TSEN2
PPARG	• SLC39A13	TSEN34
PPARGC1A	• SLC7A7	TSEN54
• PPT1	• SMAD3	• TTN
PRDM5	• SMAD4	TTR
PRICKLE1	SMARCA4	UBE3A
• PRPS	1 • SMARCB1	 UCP2
PRX	SMARCE1	VCL
PTGS:	2 • SOS1	 VRK1
PTPN [*]	II • SPRED1	 WFS1
PTRF	SPTAN1	• ZEB2
RAF1	• STAT 3	 ZMPSTE24
RAI1	STAT5	 ZNF469
Coding		
counig.	1.1 1. 1	
Medically neces	sary with criteria:	
Coding	Description	
81161	DMD (dystrophin) (eg, Duchenne/Becker muscula analysis, if performed	r dystrophy) deletion analysis, and duplication
	•	

•	PCDH19	
•	PDGFR	
•	PDLIM3	
•	PFX6	

NHLRC1

NKX2-1

NLRP3

NOMID

NOTCH1

NOTCH2

NPHS2

NRXN1

NSD1

OCA2

OPA 1

OPHN1

ΟΤΟΑ

OTOF

PAX2

PCDH15

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

- PEXO Phox2b •
- PJVK, •
- PKD2 •
- PKP1 •
- PKP2 •
- PLEC •
- PLIN1 • PLOD1 •

Medical 34C

STRC ٠

RARS2

RASA1

RBM20

RBPJ

RBP4

RNASEH2A

RNASEH2B

RNASEH2C

RPS6KA3

RYR2

SALL4

SBDS

SAMHD1

SCL9A6

SCN1A

SCN1B

SCN2A SCN4A

SCN8A

SCN9A

SCNN1B

SCNN1G

Spla2-IIA

SFTPB

SFTPC

SGCD

•

.

•

•

.

•

•

.

•

•

.

•

•

•

•

•

•

SHOX

SLC16A1

- STXBP1
- SYNGAP1 ٠
- TAS ٠
- TAS2R38 •
- TBC1D4
- •
- TCAP
- TCF4 •
- TCF7L2 •
- TECTA •
- TGFBR1
- **T**GFBR2 •

- TGM5
- TMC1 •
- •
- TMC6
- TMC8 •
- TMEM43

•

•

•

•

•

- TMIE
- TMPO
- TMPRSS3
- **TNFR1TJP2** •
- **TNFRSF1A** ٠

TNNT2

TPM1

TPP1

TPRN.

Page 12 of 19

- TNNC1 ٠
- TNNI3 •

81187	CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81200	ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A,
81209	BLM (Bloom syndrome, RecQ helicase-like) (eg, Bloom syndrome) gene analysis, 2281del6ins7 variant
81220	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, ACMG/ACOG guidelines)
81221	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; known familial variants
81222	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants
81224	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility)
81228	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, Bacterial Artificial Chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)
81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities;
81234	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)
81239	DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)
81242	FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis, common variant
81243	FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81244	FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)
81250	G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X)
81255	HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, common variants (eg, 1278insTATC, 1421+1G>C, G269S)
81256	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence
81260	IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P)
81271	HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
81274	HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)
81280	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); full sequence analysis
81281	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); known familial sequence variant

81282	Long QT syndrome gene analyses (eg, KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); duplication/deletion variants
81284	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles
81285	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)
81289	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)
81290	MCOLN1 (mucolipin 1) (eg, Mucolipidosis, type IV) gene analysis, common variants (eg, IVS3- 2A>G, del6.4kb)
81329	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed
81330	SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, Niemann-Pick disease, Type A) gene analysis, common variants (eg, R496L, L302P, fsP330)
81332	SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common variants (eg, *S and *Z)
81336	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence
81337	SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)
81400	Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis)
81401	Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat)
81402	Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD])
81403	Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
81404	Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
81406	Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons)
81407	Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)
81408	Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis)

81412	Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM,
	CETR, FANCE, GBA, HEXA, IKBKAP, MEDLINT, and SMPDT
81439	Hereditary cardiomyopathy (eg, hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), genomic sequence analysis panel, must include sequencing of at least 5 cardiomyopathy-related genes (eg, DSG2, MYBPC3, MYH7, PKP2, TTN)
81443	Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)
81479	Unlisted molecular pathology procedure
88230	Tissue culture for non-neoplastic disorders; lymphocyte
88248	Chromosome analysis for breakage syndromes; baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (eg, for ataxia telangiectasia, Fanconi anemia, fragile X)
88289	Chromosome analysis; additional high resolution study
0233U	FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions
S3841	Genetic testing for retinoblastoma
Considered Not	t Medically Necessary:
Coding	Description
81177	ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles
81223	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence
81252	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence
81253	GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants
81254	GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (eg, nonsyndromic hearing loss) gene analysis, common variants (eg, 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13S1854)])
81257	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; common deletions or variant (eg, Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, Constant Spring)
81258	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant
81259	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; full gene sequence
81269	HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion variants
81302	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis

81303	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant
81304	MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; duplication/deletion variants
81324	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis
81325	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81326	PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant
81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
81333	TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)
81361	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)
81363	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); duplication/deletion variant(s)
81364	HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); full gene sequence
81410	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); genomic sequence analysis panel, must include sequencing of at least 9 genes, including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, and MYLK
81411	Aortic dysfunction or dilation (eg, Marfan syndrome, Loeys Dietz syndrome, Ehler Danlos syndrome type IV, arterial tortuosity syndrome); duplication/deletion analysis panel, must include analyses for TGFBR1, TGFBR2, MYH11, and COL3A1
81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81416	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81417	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (eg, updated knowledge or unrelated condition/syndrome)
81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81426	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
81430	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); genomic sequence analysis panel, must include sequencing of at least 60 genes, including CDH23, CLRN1, GJB2, GPR98, MTRNR1, MYO7A, MYO15A, PCDH15, OTOF, SLC26A4, TMC1, TMPRSS3, USH1C, USH1G, USH2A, and WFS1

81431	Hearing loss (eg, nonsyndromic hearing loss, Usher syndrome, Pendred syndrome); duplication/deletion analysis panel, must include copy number analyses for STRC and DFNB1 deletions in GJB2 and GJB6 genes
81554	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
83529	Interleukin-6 (IL-6)
S3800	Genetic testing for amyotrophic lateral sclerosis (ALS)
S3852	DNA analysis for APOE epsilon 4 allele for susceptibility to Alzheimer's disease
S3861	Genetic testing, sodium channel, voltage-gated, type V, alpha subunit (SCN5A) and variants for suspected Brugada Syndrome

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2024: May
- 2023: October
- 2022: November
- 2022: August
- 2022: May
- 2022: March
- 2021: September
- 2021: May
- 2020: December
- 2020: October
- 2020: September
- 2020: June
- 2020: May
- 2020: March
- 2020: January
- 2019: December
- 2019: October
- 2018: March
- 2017: September
- 2016: August
- 2016: June
- 2016: May
- 2016: April
- 2016: February
- 2016: January
- 2015: December
- 2015: November
 2015: October
- 2015. October
 2015. Sontomk
- 2015: September

Reviewed Dates:

- 2019: October
- 2017: May
 - 2015: November

- 2015: August
- 2015: July
- 2015: June
- 2015: May
- 2015: April
 2015: March
- 2015: March 2015: February
- 2015: February
 2015: January
- 2013: January 2014: December
- 2014: December
 2014: November
- 2014: Novemb
 2014: October
- 2014: September
- 2014: Septem 2014: August
- 2014. Augus 2014: July
- 2014. July 2014: June
- 2014: Ju
- 2014: May
- 2014: April
- 2014: March
- 2014: February
- 2014: January
- 2013: December
- 2013: November
- 2013: October
- 2013: August
- 2013: July
- 2013: June
- 2013: May
- 2013: April
- 2013: March

- 2013: February
- 2013: January
- 2012: December
- 2012: November
- 2012: October
- 2012: September
- 2012: August
- 2012: July
- 2012: June
- 2012: May
- 2012: April
- 2012: March
- 2012: February
- 2012: January
- 2011: December
- 2011: November
- 2011: October
- 2011: September
- 2011: August
- 2011: July
- 2011: June
- 2011: May
- 2011: April
- 2011: March
- 2011: February
- 2011: January
- 2010: November
- 2010: April
- 2009: November

• 2010: February

Effective Date:

• February 2009

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023, Sep 21). Retrieved Apr 11, 2024, from MCG: https://careweb.careguidelines.com/ed27/index.html

(2024). Retrieved Apr 11, 2024, from Hayes - a symplr company: https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522skeletal%2520disorders%2520testing%

2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522 page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,

(2024). Retrieved Apr 11, 2024, from Google - Specialty Guideline Search: <u>https://www.google.com/search?q=recommendation+for+skeletal+disease+genetic+testings&safe=strict&sca_esv</u> <u>=fd299e0f5b2672c9&sca_upv=1&rlz=1C1GCEJ_enUS1093US1093&sxsrf=ACQVn0-</u> <u>nFi1n8smP7Vgj8eTPuG9UqWbrEA%3A1712853640879&ei=iBIYZteVNayk5NoP9-al0Ak&ved=0ahUKEwj</u>

(2024). Retrieved Apr 11, 2024, from Department of Medical Assistance Services - MES Public Portal: <u>https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-</u> <u>library#gsc.tab=0&gsc.g=genetic%20testing&gsc.sort=</u>

(2024). Retrieved Apr 11, 2024, from Centers for Medicare and Medicaid Services: <u>https://www.cms.gov/medicare-coverage-database/search-</u> <u>results.aspx?keyword=skeletal+disorder+testing&keywordType=starts&areald=all&docType=NCA,CAL,NCD,MED</u> <u>CAC,TA,MCD,6,3,5,1,F,P&contractOption=all</u>

Glanc, P., & Chitayat, D. (2022, Jan 03). Approach to prenatal diagnosis of the lethal (life-limiting) skeletal dysplasias. Retrieved Apr 11, 2024, from UpToDate: <u>https://www.uptodate.com/contents/approach-to-prenatal-diagnosis-of-the-lethal-life-limiting-skeletal-</u>

dysplasias?search=genetic%20testing%20for%20skeletal%20disorders&source=search_result&selectedTitle=2% 7E150&usage_type=default&display_rank=2#H2039921050

Invitae Skeletal Disorders Panel. (2024). Retrieved Apr 11, 2024, from Invitae: <u>https://www.invitae.com/us/providers/test-catalog/test-89100</u>

Regulation of Genetic Tests. (2024, Feb 19). Retrieved Apr 11, 2024, from U.S. Food and Drug Administration: <u>https://www.genome.gov/about-genomics/policy-issues/Regulation-of-Genetic-Tests</u>

Special Notes: *

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan individual should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice,

although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family individual covered under the Plan. Call Member Services if You have questions.

Keywords:

Amyloidosis, Ashkenazi Jewish, Autosomal recessive, Bloom syndrome, CADASIL, Canavan disease, Carrier Testing, CD40 Ligand Deficiency, CD40LG, Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, CFTR, CGH Array, Congenital adrenal hyperplasia, Congenital Muscular Dystrophy panel, CYP21A, Cystic Fibrosis, Deficiency, Dihydrolipoamide dehydrogenase, DMD, DNA testing, Duchene Muscular Dystrophy, Dysautonomia, EDMD1, 2, and 3, Emery-Dreifuss Muscular Dystrophy, Familial Hemophagocytic Lymphohistiocytosis, Familial Hypercholesterolemia, Familial hyperinsulinism, Familial Myotonic Dystrophy, Family history, Fanconi Anemia, Fascioscapulohumeral Muscular Dystrophy, FMR1, Fragile X syndrome, Friedreich Ataxia, Fructose Intolerance Testing, FSHD, FXN, Gaucher's disease, Glycogen storage disease type 1, HCM, Hereditary Hypertrophic Cardiomyopathy, HTT, Huntington Disease, Hyper IgM, Inheritest Universal screening, Karyotype, Limb girdle Muscular Dystrophy, Long QT, Maple syrup urine disease, Marfan syndrome, Mckusick-Kaufman Syndrome, Morquio syndrome, Mucolipidosis, Mucopolysaccharidosis, Muscular Dystrophy, Nemaline myopathy, Neurofibromatosis, Nieman Pick Disease, PAH, Phenylalanine hydroxylase, phenylketonuria, PKU, Preimplantation, Premature coronary heart disease, Retinoblastoma, Riley-Day syndrome, SERPINA1, Single nucleotide polymorphism, SNP Microarray, Spinal Muscular Atrophy, Tay-Sach's, Ullrich Muscular Dystrophy, Usher syndrome type 1F, WAS, Wiskott-Aldrich syndrome, Xanthomas, X-linked,